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Background: Although no receptor has yet been identified, changes in circulating levels of the adipokine
designated as Omentin have been demonstrated in obesity and related comorbidities such as cardiovascular
disease, insulin resistance, metabolic syndrome and chronic inflammation.
Methods: Changes in Omentin levels at 1 and 5 days and 6 and 12 months in response to biliopancreatic diversion
with duodenal switch bariatric surgery were evaluated, specifically to investigate if changes preceded gain of insulin
sensitivity.
Results: Pre-operative plasma Omentin was not different between men (n = 18) vs women (n = 48), or diabetic
status but correlated with body mass index (BMI). Altogether, Omentin increased as early as 24-h post-surgery, with
changes maintained up to 1-year. Fifty-nine percent of subjects increased Omentin >10% by 24-H following surgery
(OmentinINC p < 0.0001), while 18% of subjects decreased (OmentinDEC p < 0.0001), with changes maintained
throughout one-year. These two groups had comparable age, sex distribution, diabetes, BMI, waist circumference
and fat mass, however OmentinDEC had elevated levels of cardiovascular risk markers; homocysteine (p = 0.019),
NT-proBNP (p = 0.006) and total bilirubin (p = 0.0001) while red blood cell (RBC) count was lower (p = 0.0005)
over the one-year period. Omentin levels at 1-DAY also correlated with immune parameters (white blood cell
count, % neutrophil, % monocytes, % lymphocytes).
Conclusion: OmentinDEC at 1 day following surgery may be a marker of cardiovascular “at-risk” group before
weight loss or insulin sensitivity restoration.
Keywords: Obesity, Weight loss, NT-proBNPBackground
A recently described adipokine, Omentin, has gained
interest lately following reports of associations with various
comorbidities stemming from obesity such as cardiovascu-
lar disease, insulin resistance and metabolic syndrome
(reviewed in [1]). Omentin expression varies throughout
the body (heart, lungs, ovary and placenta) but its main tis-
sue of production is now considered to be visceral adipose
tissue [2,3]. First identified in intestinal Paneth cells, Omen-
tin demonstrates low affinity binding to bacterial cell wall* Correspondence: katherine.cianflone@criucpq.ulaval.ca
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unless otherwise stated.carbohydrates and was thought to be part of early-defense
mechanisms in the gut against pathogenic bacteria [4].
In obesity, Omentin levels are decreased and are in-
versely correlated to body mass index (BMI), waist cir-
cumference and leptin concentration [5]. Omentin levels
correlate inversely with markers of metabolic syndrome
[6-8] and is decreased in patients with heart disease.
Omentin has been suggested to be an even better
marker than adiponectin of patients at risk for coronary
artery disease [9]. Other studies have also shown a sig-
nificant decrease in Omentin in subjects with demon-
strated carotid plaque in combination with type 2
diabetes vs patients with type 2 diabetes with no
plaque vs glucose tolerant subjects [10]. This relation-
ship with insulin resistance is further reported in manyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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paired glucose tolerance or with diabetes also had de-
creased Omentin levels [11,12]. During weight loss due to
diet or an exercise regimen, Omentin levels increased over
time [13,14], further solidifying its link to obesity and body
weight.
Omentin has also been linked to chronic inflamma-
tion, with reduced levels in rheumatoid arthritis, Crohn’s
disease and asthma (reviewed in [1]). All these studies
point towards a possible link between this visceral adi-
pose tissue produced hormone and a diseased state.
In vitro, Omentin enhances insulin-stimulated glucose
uptake in human adipocytes as well as activating Akt
signaling pathways [3]. Pre-treatment of rat cells with
Omentin significantly decreased TNF-α mediated phos-
phorylation of p38 and JNK, expression of VCAM-1,
monocyte adhesion to smooth muscle cells, and NOX-
derived superoxide production [4]. In adipose tissue ex-
plants, both insulin and glucose decrease Omentin mRNA
expression and secretion [15]. To date, no receptor has
been identified for intracellular transduction of these
functions.
Severely obese patients have few options for weight
loss and resolution of comorbidities that are as effective
as bariatric surgery [16]. In fact, bariatric surgery was re-
cently recognized as a valid treatment option for type 2
diabetes in obese patients by both the International Dia-
betes Federation and the American Diabetes Association.
Further, long-term (6-year) remission rates post-gastric
bypass reached up to 31% in a study by Brethauer et al.
[17] and up to 72% in the Swedish Obese Subjects Study
(SOS; with a follow-up of 2 years) [18], and result in im-
provements in cardiovascular function [19]. Biliopan-
creatic diversion (BPD) with or without duodenal switch
(DS) is frequently used and has shown improvement in
insulin and glucose metabolism in most patients [20]. As
Omentin has demonstrated insulin-sensitizing effects
and because patients undergoing BPD-DS become more
insulin-sensitive mere days following surgery, even be-
fore any weight loss [21], Omentin levels were evaluated
in a cohort of BPD-DS patients in the early stages post-
surgery (1 day and 5 days, prior to weight loss) and over
a longer period (6 months and 1 year, a period associ-
ated with weight loss). Specifically, we propose that
Omentin levels will increase post-bariatric surgery and
that this rise will precede gain of insulin sensitivity.
Methods
Subjects
Men and women >18 years of age were recruited into
this study before undergoing biliopancreatic diversion
(BPD) with duodenal switch (BPD-DS) at the Institut
Universitaire de Cardiologie & Pneumologie de Québec
(IUCPQ). Inclusion criteria were a BMI ≥40 kg/m2 or≥35 kg/m2 with associated comorbidities. Patients who
had previously undergone bariatric surgery or bore a
pacemaker were excluded. Further, only patients for
whom blood samples were taken at all 5 time points
(pre-operative, day 1, day 5, 6 months and 1 year post-
operatively) were included for further analysis. All la-
boratory measurements were finalized before statistical
analyses were begun. All patients gave their informed,
written consent; the protocol was approved by the ethics
committee of the Research Center of IUCPQ, affiliated
with Laval University.
Anthropometric data
Height was measured with a stadiometer (SECA, 216
1814009, Brooklyn, NY). Weight, BMI, fat and lean
masses were measured with an electrical bioimpedance
balance (Tanita TBF-310, Tokyo, Japan) following a
12-hour fast. Medical history and treatments were col-
lected from clinical file consultations.
Plasma analyses
Blood samples were collected following a 12-hour fast
into EDTA containing tubes and kept on ice until centri-
fugation (within 15 minutes). Plasma was then aliquoted
into microtubes and stored at −80°C until analysis. Gly-
cated hemoglobin (HbA1c) was measured in fresh sam-
ples by turbidimetric inhibition immunoassay. Standard
clinical methodology (hospital biochemistry laboratory)
was used to measure biochemical parameters while
high-sensitive C-reactive protein (hsCRP) and apolipo-
protein B (apoB) levels were measured by immunoturbidi-
metric method (Integra 800 System, Roche Diagnostics, IN,
USA). All other biochemical assays were performed using a
Modular system (Roche Diagnostics). LDL-cholesterol
concentration was calculated using the Friedewald for-
mula [22]. Homeostatic model assessment of insulin
resistance (HOMA-IR) was calculated from fasting
plasma insulin and glucose levels as (insulin × glu-
cose)/22.5, where insulin concentration is converted
from pmol/L to milliunits per liter and glucose as mil-
limolar concentrations. Omentin was measured using
Enzo Life Sciences (Farmingdale, NY, USA) ELISA
which has a sensitivity of 0.4 ng/mL. Intra- and inter-
assay CV% error are reported by the manufacturer as
being <7.4% and <9.3%, respectively.
Statistical analysis
Data are expressed as mean ± SEM as indicated. Student
T or Chi2 tests were used to assess differences between
individual variables or time points. For comparisons
across multiple time points, repeated measures ANOVA
with Holm-Sidak post-tests was used. Relationships be-
tween variables in each group were assessed by linear
regression analysis using Spearman correlation. Prism
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(Systat Software Inc., San Jose, CA, USA) software pro-
grams were used for graph and statistical analyses. Sig-




As shown in Table 1, 18 men and 48 women undergoing
BPD-DS were recruited in this study. Fifty percent of the
patients (n = 33) had type 2 diabetes and 31 were receiv-
ing drug regimen before surgery. Subjects were an averageTable 1 Pre-operative levels in all subjects
Variables All subjects
(n = 66) ± SEM
Men/Women 18/48
Diabetic/Non-diabetic 33/33
T2D treatment 31/33 (94%)
Lipid lowering treatments 30/66 (45%)
Age (years) 46.7 ± 1.3
Weight (kg) 136 ± 3
BMI (kg/m2) 49.6 ± 0.1
Lean mass (kg) 65.8 ± 1.7
% fat mass 51.3 ± 0.7
Omentin (ng/mL) 11.0 ± 0.6
Glucose (mmol/L) 6.72 ± 0.29
Insulin (pmol/L) 195 ± 17
HOMA-IR 8.81 ± 0.95
Fructosamine (μmol/L) 215 ± 4
HbA1c (%) 6.20 ± 0.01
Cholesterol (mmol/L) 4.64 ± 0.11
Triglycerides (mmol/L) 1.63 ± 0.13
LDL (mmol/L) 2.64 ± 0.09
HDL (mmol/L) 1.29 ± 0.04
apoB (g/L) 0.77 ± 0.02
White blood cells (% total blood cell count) 8.10 ± 0.30
Neutrophils (% of white blood cells) 63.0 ± 1.00
Monocytes (% of white blood cells) 7.00 ± 0.20
Lymphocytes (% of white blood cells) 27.0 ± 1.00
Red blood cells (Total cell count ×1012/L) 4.60 ± 0.05
ASP (nmol/L) 32.2 ± 2.30
IL-6 (pg/mL) 8.19 ± 1.03
Hemoglobin (nmol/L) 136 ± 1
Total Bilirubin (μmol/L) 7.77 ± 0.42
NT-proBNP (pg/mL) 50.9 ± 5.8
Homocysteine (μmol/L) 10.1 ± 0.5
Abbreviations: BMI body mass index, WBC white blood cells, * p = 0.025.of 46.7 ± 1.3 years old with a BMI of 49.6 ± 0.1 kg/m2. Aver-
age HOMA-IR was 8.81 ± 0.95, demonstrating generalized
insulin resistance, as also indicted by elevated fructosamine
(215 ± 4 μmol/L) and HbA1c (6.20 ± 0.01%) levels. Circulat-
ing hepatic and cardiac related risk markers were within
normal clinical ranges (bilirubin, calcium, N-terminal pro-
brain natriuretic peptide (NT-proBNP), gamma-glutamyl
transpeptidase (GGT), and homocysteine). Red blood cell
count, hemoglobin and hematocrit levels were within the
normal range. Acylation Stimulating Protein (ASP; 32.2 ±
2.3 nmol/L) and IL-6 (8.19 ± 1.03 pg/mL) were also
measured.Range Omentin-INC
(n = 39) ± SEM
Omentin-DEC





26.4 - 68.3 47.0 ± 1.7 46.6 ± 3.8
94 - 205 134 ± 5 130 ± 6
35.9 - 75.5 48.8 ± 1.3 50.7 ± 1.7
48.6 - 116.6 68.9 ± 3.1 68.8 ± 4.1
33.8 - 66.8 51.0 ± 0.9 53.0 ± 0.9
2.2 - 22.0 9.8 ± 0.8 11.7 ± 1.4
4.20 - 16.00 6.52 ± 0.33 6.28 ± 0.96
43 - 846 208 ± 25 200 ± 41
1.51 - 39.91 9.16 ± 1.30 8.65 ± 2.68
161 - 320 214 ± 5 211 ± 14
4.00 - 9.00 6.00 ± 0.16 0.061 ± 0.003
2.72 - 7.53 4.60 ± 0.14 4.68 ± 0.17
0.53 - 7.47 1.57 ± 0.15 1.40 ± 0.12
1.21 - 4.57 2.64 ± 0.11 2.60 ± 0.15
0.65 - 2.26 1.26 ± 0.05 1.39 ± 0.11
0.43 - 1.19 0.77 ± 0.03 0.80 ± 0.05
3.20 - 21.40 7.68 ± 0.26 8.20 ± 0.76
46.0 - 60.0 62.3 ± 0.9 62.6 ± 2.3
3.00 - 12.00 6.75 ± 0.29 7.27 ± 0.80
24.0 - 35.0 27.8 ± 0.8 27.3 ± 2.0
3.74 - 5.60 4.65 ± 0.06 4.44 ± 0.12
9.9 - 87.6 29.1 ± 2.8 31.2 ± 4.3
0.01 - 59.67 8.41 ± 1.68 6.84 ± 1.19
102 - 170 139 ± 2 132 ± 3
3.00 - 23.00 7.39 ± 0.45 10.00 ± 1.43*
5.0 - 226.0 50.4 ± 7.9 78.6 ± 26.2










































































Figure 1 Circulating Omentin levels and correlations in
preoperative state. Fasting Omentin levels in the preoperative
state were measured in all subjects. A: Fasting Omentin levels
separated based on sex and presence/absence of diabetes. Results
are given as mean ± SEM. B and C: Correlation (Spearman) of
Omentin levels to lymphocyte counts and circulating acylation
stimulating protein (ASP).
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count and adipokines
Average preoperative Omentin levels were 11.0 ± 0.6 ng/mL,
ranging from 2.2 to 22.0 ng/mL (Table 1). Pre-operative
plasma Omentin levels were not significantly different
in men vs women and were not affected by diabetic
status (Figure 1A). Lymphocytes and ASP were posi-
tively correlated with Omentin (p = 0.046, Figure 1B
and p = 0.019, Figure 1C, respectively).
Omentin levels increase acutely post-surgery
Figure 2 shows Omentin levels before and after BPD-DS
surgery in the total group. A rapid increase of Omentin
can be seen as early as 24 hours post-surgery and this
increase is maintained up to 1 year after the surgery.
Post-op Omentin levels differentiate into two groups
Of the 66 patients enrolled in the study, most (39 of 66;
59%) had Omentin levels that increased acutely at one-
day following surgery (OmentinINC Figure 2B, p < 0.0001
by paired t-test) while in 12 patients (18%) Omentin de-
creased >10% acutely following the surgery (OmentinDEC
Figure 2B, p < 0.0001 by paired t-test). A group of 15 pa-
tients (23%) showed no overall significant change in
their Omentin levels at one-day post-surgery (p = NS by
paired t-test). As these variations of Omentin were
within the inter-assay variation coefficient of the ELISA
(<10%), they were excluded from further analysis
(Omentin-neutral group, Figure 2B). In those patients
with acute changes at 1 day, these changes persisted
throughout the follow-up, and were evident both at
5 days (prior to any change in weight) as well as long
term (6 months and 12 months) with substantial weight
loss. As seen in Figure 2C, although the groups are de-
fined based on 1-DAY changes, they remain significantly
different at each of the subsequent time periods as well
as over the one year follow-up period (p = 0.002), with
OmentinINC patients maintaining higher Omentin levels
throughout the 1-year period and OmentinDEC patients
also maintaining lower levels throughout.
OmentinINC and OmentinDEC groups: acute 1-day changes
in omentin levels correlate with long-term (1 year) health
parameters
At baseline, subjects separated by acute (1-DAY) changes
in Omentin were not significantly different in terms of
pre-operative age, sex distribution, presence of diabetes or
lipid lowering therapy, BMI, waist circumference, fat mass,
or any of the fasting circulating variables measured as
listed in Table 1, including glucose and lipid parameters
(Table 1). Only total bilirubin was elevated in the Omen-
tinDEC group, 10.00 ± 1.43 μmol/L vs OmentinINC 7.39 ±



















































































Figure 2 Fasting pre-operative and post-operative Omentin
levels. A: Fasting levels of Omentin were measured pre-operative,
and at 1 day, 5 days, 6 months and 12 months post-operatively.
Results are presented as average ± SEM with analysis by ANOVA vs
pre-operative levels. B: Pre-operative and 1 day levels of Omentin
are given individually for subjects separated based on >10% increase
(OmentinINC), >10% decrease (OmentinDEC), and no change in
Omentin (neutral = OmentinNEU). C: Percent Omentin change
across all time points is given for the OmentinINC (solid line) and
the OmentinDEC (dotted line) group. Results are presented as
average ± SEM with analysis by 2-way ANOVA. Significance is
presented as *p < 0.05, **p < 0.01 and ***p < 0.001.
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surgery had elevated levels of homocysteine (p = 0.019),
NT-proBNP (p = 0.006) and total bilirubin (p = 0.0001)
while red blood cell (RBC) count was lower (p = 0.0005)
over the total study period (Figure 3). These differences be-
tween the two groups were not confounded by such pa-
rameters as weight (pre-surgery) or weight loss (up to
1 year after surgery) as all patients lost the same average
amount of weight as shown by BMI (6-month BMI: Omen-
tinDEC group 36.72 ± 1.52 kg/m
2 vs OmentinINC 35.72 ±
1.02 kg/m2, p = ns and 12-month BMI: OmentinDEC group
30.54 ± 1.37 kg/m2 vs OmentinINC 30.72 ± 0.90 kg/m
2,
p = ns). Further, the resolution of diabetes within both
groups was rapid and comparable.
Weight and inflammation correlate overall with acute
changes in Omentin levels
Baseline pre-surgery BMI inversely correlated (p = 0.008)
with the acute 1-day changes in Omentin levels and this
was reflected in both total weight and fat mass correla-
tions (p = 0.048 and p = 0.037, respectively). As well, IL-6
levels before surgery also inversely correlated with the
acute changes in Omentin (p = 0.02, Table 2).
Further, in the groups as a whole, levels of Omentin at
1-day following surgery correlated with many immune-
and blood-related parameters. White blood cell count
changes at 6 months and 1 year were inversely corre-
lated with Day-1 Omentin levels (p = 0.016 and p <
0.001, respectively) as were neutrophil values (% total
white cell count, p = 0.01 at 6 months and p = 0.022 at
1 year). Additionally, % monocytes and % lymphocytes
correlated positively with Day-1 Omentin (p = 0.002,
1 year and p = 0.027, 6 months, respectively). One-year
hemoglobin and total bilirubin levels at 6 months (p <
0.005 and p = 0.006, respectively) both correlated nega-
tively as shown in Table 3.
Discussion
The adipokine Omentin has been increasingly implicated
in metabolic dysfunctions. Pre-surgery values of Omen-
tin positively correlated with both BMI and ASP levels.























































































































Figure 3 Pre-operative and post-operative results for cardiovascular risk factors presented for groups based on OmentinINC and
OmentinDEC. Preoperative and postoperative results are presented for homocysteine (A), NT-proBNP (B), total bilirubin (C) and red blood cell
counts (D) for the OmentinINC (solid line) and OmentinDEC (dotted line) groups over one year follow-up. Results are expressed as average ± SEM
with analysis by 2-way ANOVA, significance for groups difference is indicated with post-hoc comparisons indicated: *** p < 0.001.
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however our correlations may be confounded by the
subjects, which were all severely obese. In the present
study, changes that occurred in Omentin levels following
BPD-DS were evaluated both in the short-term as well
as up to one year following surgery. As expected, sub-
jects showed significant weight loss in the months fol-
lowing BPD-DS. In corroboration with other weight loss
studies [14] we show that, in a large proportion of the
patients, Omentin levels increase post-operatively. Inter-
estingly, this change in Omentin occurred even before
induction of weight loss, and these levels were main-
tained up to one-year post-bariatric intervention. Specif-
ically, the Omentin increase occurred by one day post-Table 2 Correlations between pre-operative variables and
acute 1-DAY changes in Omentin
Pre-op parameters % 1D OM p=
Weight (kg) −0.263 0.048
Fat Mass (kg) −0.277 0.037
BMI (kg/m2) −0.347 0.008
IL-6 (pg/mL) −0.316 0.020surgery, even prior to resolution of the diabetic status,
which occurred in many of these subjects by 5 days
post-surgery [21]. However, not all patients demon-
strated this Omentin increase following BPD-DS. In fact,
18% saw their levels decrease >10% by 24 hours after
surgery but still demonstrated a resolution of their dia-
betic status in the short-term post-surgery. Further, these
decreased levels were consistently maintained up to
1 year following the surgery.
Interesting differences could also be seen between the
groups, OmentinDEC and OmentinINC, at various time
points. OmentinDEC group was characterized by eleva-
tion of markers related to heart disease (both short- and
long-term). Homocysteine, bilirubin and red blood cell
counts were significantly different between the two
groups throughout the one-year follow-up period, while
NT-proBNP showed an overall difference but a peak dif-
ference at day 5 post-surgery. Increases in NT-proBNP
have been linked to increased mortality rates in patients
and several studies have proposed this as a marker of left
ventricular diastolic dysfunction and heart failure
[23-26], although in the present study the patients have
not been followed up long enough, or with these out-
comes as study criteria.
Table 3 One-day post-surgery levels of Omentin correlation with long-term health parameters
Δ183D Δ365D
Variables Correlation coefficient p Correlation coefficient p
White blood cell count (109/L) −0.322 0.016 −0.448 <0.001
% neutrophils (% of white blood cells) −0.341 0.010 −0.301 0.022
% monocytes (% of white blood cells) - - 0.396 0.002
% lymphocytes (% of white blood cells) 0.296 0.027 - -
Hemoglobin (nmol/L) - - −0.361 0.005
Bilirubin, total (μmol/L) −0.336 0.006 - -
Abbreviations: WBC white blood cell.
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also linked to left ventricular diastolic function as well as
coronary artery disease [27,28]. Levels of this non-
protein α-amino acid can reflect vitamin intake, espe-
cially vitamin B6, which is needed as a cofactor for the
transformation of homocysteine into cysteine [28,29].
Thus, in a cohort of patients receiving not only restrict-
ive but also malabsorptive surgery, vitamin intake could
well play a significant role in homocysteine levels. Pa-
tients receive high doses of vitamins to curtail any nega-
tive impact of bariatric surgery and although patient
compliance can never be fully assured, vitamin A, D,
B12 and folate levels remained within normal healthy
parameters up to 1 year post-surgery (data not shown).
Elevated bilirubin levels have been shown to correlate
with increased heart failure and death and corroborate the
observations made with the previously mentioned bio-
markers [30,25]. By contrast, other studies demonstrate
that lower bilirubin levels correlate closely to coronary
heart disease and metabolic syndrome components [31,32].
Further, bilirubin is the end-product of heme degradation
which would be consistent with the observation of lowered
red blood cell count in the OmentinDEC group. Interest-
ingly, bilirubin levels are elevated before the surgery in this
group of patients (as well homocysteine), suggesting that
these patients are already more at risk, even before any
changes in diabetic status or Omentin levels.
Other studies have reported a link between Omentin
and heart disease. Moreno-Navarette et al. suggested
that Omentin, after controlling for adiposity, age, and in-
flammation in patients with impaired glucose tolerance,
contributed independently to endothelial dysfunction
[13]. A very recent study [33] shows that patients with
lower levels of Omentin had increased risk of heart fail-
ure and even suggest its use as a novel prognostic
marker for risk stratification in heart failure patients.
This is further reinforced mechanistically by a study
from Kataoka and colleagues [34], where systemic injec-
tion of Omentin in mice that suffered sustained ischemic
injury led to a reduction of myocardial infarct size and
apoptosis. Further, studies have also shown lower Omen-
tin levels in patients with type 2 diabetes compared tohealthy controls and even lower Omentin levels when pa-
tients with diabetes presented with carotid plaque [10].
While the functions of Omentin are still being eluci-
dated and its receptor is still unknown, a role as “insulin
sensitizer” in adipocytes has already been demonstrated.
However, recent evidence supports the potential for an
as yet unidentified role in heart function based on the
links to heart disease. Interestingly, pre-operative BMI
(as well as weight and fat mass) correlated negatively
with the acute (1 day) change in Omentin, as did IL-6
levels, perhaps indicating that a subgroup of these se-
verely obese patients are already at-risk for the develop-
ment of cardiovascular problems and this could be
associated with Omentin (and other factors) in an as-
yet-undiscovered function. Initial studies on Omentin
(then known as Intelectin) focused on its microbial sur-
face galactofuranose binding properties. Thus, it was
suggested to participate in host early-defense against
bacterial infections [35]. Literature in recent years has
shown the importance of gut microbiota in the develop-
ment of obesity as well as insulin resistance and other
metabolism-related comorbidities (as reviewed in [36]).
We would speculate that Omentin could be part of this
link, being produced by visceral adipose tissue and act-
ing as an “insulin sensitizer” yet also being able to inter-
act with specific bacteria in the gut. BPD-DS also plays a
role in post-surgery microbiota redistribution (reviewed
in [37]) and this could possibly be evidenced through
changes in Omentin levels. Further, Omentin has dem-
onstrated anti-inflammatory properties, cementing its
links with CVD and Metabolic Syndrome (reviewed in
Jaikanth et al. [1]. Thus, lower levels of this adipokine
could well be implicated in worsening of situations
where immune activation is present, as is the case in
obesity and diabetes. These proposed roles of Omentin,
and correlations with ASP and lymphocytes, mesh with
the concept of the contribution of various biomarkers to
an enhanced pro-inflammatory state and autoimmune
activation as pivotal in understanding chronic diseases,
as reviewed in detail by Onat et al. [38].
The limitations of this present study are that all pa-
tients were severely obese, and as such interpretations
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exploratory nature of Omentin physiology, with little
known regarding regulation, signaling pathway, receptor
target and broader functions in various tissues, the
current correlations cannot be interpreted as causative.
Further studies will be necessary to determine the pos-
sible links between Omentin and risk of heart failure
and whether this novel adipokine could be used as an
early biomarker to identify patients with increased risk,
and whether special care or treatment should be
administered.
Conclusions
Altogether, the present study suggests that a subgroup
of patients (approximately 25%) following bariatric sur-
gery may be at greater risk for heart-related complica-
tions, at least based on the presentation of known risk
markers, both preoperatively and within the one year
follow-up period following surgery. Further, Omentin
levels 1 day following surgery may be a marker of this
“higher risk” group, where lowered Omentin correlates
with higher levels of risk factors overall, well before any
weight loss or changes in adiposity and before insulin
sensitivity is restored.
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